Combating the Complexities of Cancer Care During Pregnancy
Combating the Complexities of Cancer Care During Pregnancy
Optimizing Quality & Safety Systems to Reduce the Risk of Patient Harm
Optimizing Quality & Safety Systems to Reduce the Risk of Patient Harm
Managing Immunotherapy Toxicities in Lung Cancer Patients
Managing Immunotherapy Toxicities in Lung Cancer Patients
Selecting Therapy for ER+/HER2- Metastatic Breast Cancer: Key Factors to Consider
Selecting Therapy for ER+/HER2- Metastatic Breast Cancer: Key Factors to Consider
A Review of the Multiple Myeloma Treatment Journey
A Review of the Multiple Myeloma Treatment Journey
Reevaluating Platinum Rechallenge in SCLC: Challenging the Status Quo
Reevaluating Platinum Rechallenge in SCLC: Challenging the Status Quo
Understanding the Biological and Clinical Rationale for PARP Inhibitor Combinations as Potential Treatment for Prostate Cancer
Understanding the Biological and Clinical Rationale for PARP Inhibitor Combinations as Potential Treatment for Prostate Cancer
June 19, 2023
11:00 AM - 12:00 PM EDT
Understanding the Biological and Clinical Rationale for PARP Inhibitor Combinations as Potential Treatment for Prostate Cancer
Understanding the Biological and Clinical Rationale for PARP Inhibitor Combinations as Potential Treatment for Prostate Cancer
June 21, 2023
03:00 PM - 04:00 PM EDT
Targeting HER3 in Breast and Lung Cancers: Where We Are and Where We Are Going
Targeting HER3 in Breast and Lung Cancers: Where We Are and Where We Are Going
The Oncogenic Significance – and Promise – of HER3 in Pharmacotherapy
The Oncogenic Significance – and Promise – of HER3 in Pharmacotherapy
Better Early Than Late: CDK4/6 Inhibition in HR+, HER2- Early Breast Cancer
Better Early Than Late: CDK4/6 Inhibition in HR+, HER2- Early Breast Cancer
Keeping Pace in Lung Cancer
Personalizing Treatment in NSCLC: Early-Stage Disease (Stage I-IIIa)
Keeping Pace in Lung Cancer
Personalizing Treatment in NSCLC: Early-Stage Disease (Stage I-IIIa)
Operational Pathways for Biomarker Testing in NSCLC
Operational Pathways for Biomarker Testing in NSCLC
A Medical Oncologist Discusses a Treatment Option for Triple-Negative Breast Cancer
A Medical Oncologist Discusses a Treatment Option for Triple-Negative Breast Cancer
A Changing Paradigm for Cancer Screening: Exploring Surrogate Endpoints for an Urgent Public Health Concern
A Changing Paradigm for Cancer Screening: Exploring Surrogate Endpoints for an Urgent Public Health Concern
Understanding Unmet Needs in the Frontline Ph+ ALL Treatment Landscape
Understanding Unmet Needs in the Frontline Ph+ ALL Treatment Landscape
First-Line Treatment Option for Certain Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
First-Line Treatment Option for Certain Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Patient Journeys: An Individualized Approach to Statin Treatment for Adult Patients
Patient Journeys: An Individualized Approach to Statin Treatment for Adult Patients